Clare Keddy

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Topics

Advanced Non Small Cell Lung Cancer

Reactive Oxygen Species

Top Venues

Cancer discovery

EMBO molecular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO molecular medicine (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)